Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines
- Tuesday, December 7, 2021, 7:18
- PR Newswire
- Add a comment
BOSTON, Dec. 7, 2021 /PRNewswire/ — Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the completion of an oversubscribed $218 million Series A financing led by OrbiMed Advisors and co-led by SR One…
About the Author
admin has written 21643 stories on this site.